640 related articles for article (PubMed ID: 30306577)
21. IFITM1 Outperforms CD10 in Differentiating Low-grade Endometrial Stromal Sarcomas From Smooth Muscle Neoplasms of the Uterus.
Busca A; Gulavita P; Parra-Herran C; Islam S
Int J Gynecol Pathol; 2018 Jul; 37(4):372-378. PubMed ID: 28700435
[TBL] [Abstract][Full Text] [Related]
22. Uterine sarcomas 2013.
Sutton G
Gynecol Oncol; 2013 Jul; 130(1):3-5. PubMed ID: 23769183
[No Abstract] [Full Text] [Related]
23. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma.
Pautier P; Genestie C; Rey A; Morice P; Roche B; Lhommé C; Haie-Meder C; Duvillard P
Cancer; 2000 Mar; 88(6):1425-31. PubMed ID: 10717626
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in the treatment of sarcomas in gynecology.
Lange SS; Novetsky AP; Powell MA
Discov Med; 2014 Sep; 18(98):133-40. PubMed ID: 25227754
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical survey of mismatch repair protein expression in uterine sarcomas and carcinosarcomas.
Hoang LN; Ali RH; Lau S; Gilks CB; Lee CH
Int J Gynecol Pathol; 2014 Sep; 33(5):483-91. PubMed ID: 25083964
[TBL] [Abstract][Full Text] [Related]
26. Cyclooxygenase-2 expression in malignant mesenchymal tumors and related uterine lesions.
Matsumoto Y; Ishiko O; Sumi T; Yoshida H; Deguchi M; Nakagawa E; Haba T; Wakasa K; Ogita S; Ando Y
Oncol Rep; 2001; 8(6):1225-7. PubMed ID: 11605037
[TBL] [Abstract][Full Text] [Related]
27. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
[TBL] [Abstract][Full Text] [Related]
28. Microsatellite instability in uterine sarcomas.
Amant F; Dorfling CM; Dreyer L; Vergote I; Lindeque BG; Van Rensburg EJ
Int J Gynecol Cancer; 2001; 11(3):218-23. PubMed ID: 11437928
[TBL] [Abstract][Full Text] [Related]
29. The treatment of uterine sarcomas.
Reichardt P
Ann Oncol; 2012 Sep; 23 Suppl 10():x151-7. PubMed ID: 22987952
[TBL] [Abstract][Full Text] [Related]
30. [Interdisciplinary S2k guidelines on the diagnosis and treatment of uterine sarcomas-recommendations for surgical pathology].
Horn LC; Höhn AK; Denschlag D; Follmann M; Schmidt D
Pathologe; 2020 Nov; 41(6):621-633. PubMed ID: 32940744
[TBL] [Abstract][Full Text] [Related]
31. Does iatrogenic tumor rupture during surgery have prognostic implications for the outcome of uterine sarcomas?
Benito V; Lubrano A; León L; Molano F; Pinar B
Int J Gynecol Cancer; 2020 Nov; 30(11):1726-1732. PubMed ID: 32948637
[TBL] [Abstract][Full Text] [Related]
32. Undifferentiated Uterine Sarcomas Represent Under-Recognized High-grade Endometrial Stromal Sarcomas.
Cotzia P; Benayed R; Mullaney K; Oliva E; Felix A; Ferreira J; Soslow RA; Antonescu CR; Ladanyi M; Chiang S
Am J Surg Pathol; 2019 May; 43(5):662-669. PubMed ID: 30789359
[TBL] [Abstract][Full Text] [Related]
33. Malignant mesenchymal tumors of the uterus - time to advocate a genetic classification.
Rommel B; Holzmann C; Bullerdiek J
Expert Rev Anticancer Ther; 2016 Nov; 16(11):1155-1166. PubMed ID: 27602604
[TBL] [Abstract][Full Text] [Related]
34. State of the science: Uterine sarcomas: From pathology to practice.
Shushkevich A; Thaker PH; Littell RD; Shah NA; Chiang S; Thornton K; Hensley ML; Slomovitz BM; Holcomb KM; Leitao MM; Toboni MD; Powell MA; Levine DA; Dowdy SC; Klopp A; Brown J
Gynecol Oncol; 2020 Oct; 159(1):3-7. PubMed ID: 32839026
[No Abstract] [Full Text] [Related]
35. The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases.
Gadducci A; Sartori E; Landoni F; Zola P; Maggino T; Cosio S; Tisi G; Lissoni A; Ferrero AM; Cristofani R
Eur J Gynaecol Oncol; 2002; 23(4):295-9. PubMed ID: 12214727
[TBL] [Abstract][Full Text] [Related]
36. The role of lymphadenectomy in uterine leiomyosarcoma: review of the literature and recommendations for the standard surgical procedure.
Dafopoulos A; Tsikouras P; Dimitraki M; Galazios G; Liberis V; Maroulis G; Teichmann AT
Arch Gynecol Obstet; 2010 Sep; 282(3):293-300. PubMed ID: 20502905
[TBL] [Abstract][Full Text] [Related]
37. Systemic treatment in adult uterine sarcomas.
Desar IME; Ottevanger PB; Benson C; van der Graaf WTA
Crit Rev Oncol Hematol; 2018 Feb; 122():10-20. PubMed ID: 29458779
[TBL] [Abstract][Full Text] [Related]
38. Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.
Burghaus S; Halmen S; Gass P; Mehlhorn G; Schrauder MG; Lux MP; Renner SP; Beckmann MW; Hein A; Thiel FC
Arch Gynecol Obstet; 2016 Aug; 294(2):343-51. PubMed ID: 26711836
[TBL] [Abstract][Full Text] [Related]
39. ERBB-2 gene overexpression and amplification in uterine sarcomas.
Amant F; Vloeberghs V; Woestenborghs H; Debiec-Rychter M; Verbist L; Moerman P; Vergote I
Gynecol Oncol; 2004 Dec; 95(3):583-7. PubMed ID: 15581967
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990-2001.
Koivisto-Korander R; Butzow R; Koivisto AM; Leminen A
Gynecol Oncol; 2008 Oct; 111(1):74-81. PubMed ID: 18657852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
